Argent Biopharma (RGTLF)

OTHER OTC:RGTLF

RGTLF

Argent Biopharma

RESEARCH TOOLSreports

Argent Biopharma (RGTLF) Price & Analysis

31 Followers

RGTLF Stock Chart & Stats

$0.10

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$0.10

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $0.15

Previous CloseN/A

Volume49.00

Average Volume (3M)314.00

Market Cap

$3.04M

Enterprise Value$10.49M

Total Cash (Recent Filing)$1.02M

Total Debt (Recent Filing)$8.29M

Price to Earnings (P/E)―

Beta-0.80

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding111,109,580

10 Day Avg. Volume254

30 Day Avg. Volume314

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap3.45

Enterprise Value/Revenue91.12

Enterprise Value/Gross Profit-128.42

Enterprise Value/Ebitda-2.92

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving Gross MarginMaterial gross margin improvement in 2025 indicates the company's core product mix or pricing can generate higher incremental margins. If sustained, this provides a durable route to profitability as revenues stabilize or scale, reducing the absolute burden of fixed operating costs.

Prior Balance-sheet StrengthPositive shareholder equity in 2022 shows the business has previously reached a solvent capital structure, implying historical capacity to fund operations and absorb losses. That track record suggests potential to restore balance-sheet health with credible operational improvement or recapitalization.

Industry PositioningOperating in specialty and generic pharmaceuticals places the company in a sector with structural demand for differentiated or cost-competitive therapies. This industry positioning can support durable revenue streams and margin recovery if the company secures stable product demand or niche market share.

Bears Say

Negative Equity And Rising LeverageNegative equity across multiple years and higher 2025 debt materially constrain financial flexibility, increase insolvency risk, and heighten refinancing or covenant challenges. This structural balance-sheet weakness limits the firm's ability to invest, sustain R&D, or weather prolonged commercialization timelines.

Persistent Free Cash Flow BurnConsistent multi-year free cash flow losses and nil operating cash flow indicate the business cannot self-fund operations or growth. This ongoing cash burn creates structural dependence on external capital, increasing dilution risk and threatening continuity if markets tighten or financing terms worsen.

Sharp Revenue Contraction And Persistent LossesSevere revenue declines over consecutive years combined with large operating losses point to weak commercial traction or lost demand. Even with improved gross margins, operating expenses overwhelm profits; absent durable revenue recovery, scalability and long-term viability are at risk.

Argent Biopharma News

Argent BioPharma inks global Aquiol™ licensing deal to push into dermocosmetics

Argent Biopharma ( ($AU:RGT) ) has issued an announcement. Argent BioPharma has signed a five-year licensing and supply...

5d ago

Argent Biopharma Discloses Final Director Interest After Board Departure

Argent Biopharma ( ($AU:RGT) ) has shared an update. Argent Biopharma has announced that director Gary Hermon ceased...

24d ago

Argent Biopharma Names Andrew Chapman to Board, Discloses Indirect Shareholding

Argent Biopharma ( ($AU:RGT) ) has issued an update. Argent Biopharma has appointed Andrew Chapman as a director...

24d ago

Argent BioPharma Reshapes Board to Drive U.S. Market Push After CannPal Deal

Argent Biopharma ( ($AU:RGT) ) has provided an announcement. Argent BioPharma has overhauled its board and leadership structure...

24d ago

Argent Biopharma Expands Neuro-Immune Portfolio With CannPal Deal, CannEpil Shipment and New U.S. Patent

Argent Biopharma ( ($AU:RGT) ) has issued an update. Argent Biopharma reported quarterly progress highlighted by the completion...

1M ago

Argent BioPharma Bolsters Epilepsy Portfolio With CannPal Acquisition and Neuvis Option

Argent Biopharma ( ($AU:RGT) ) has shared an announcement. Argent BioPharma has completed the acquisition of AusCann Group...

2M ago

Argent BioPharma Grants Performance-Linked Shares to Director

Argent Biopharma ( ($AU:RGT) ) just unveiled an update. Argent BioPharma has disclosed a change in director Gary...

2M ago

Argent BioPharma Clears Resale Path for New Share Issue Under Disclosure Exemption

Argent Biopharma ( ($AU:RGT) ) has provided an update. Argent BioPharma has issued 21,917,267 fully paid ordinary shares...

2M ago

Argent Biopharma Issues 17 Million Unquoted Performance Rights

Argent Biopharma ( ($AU:RGT) ) has shared an update. Argent Biopharma Limited has notified the Australian Securities Exchange...

2M ago

Argent Biopharma Seeks ASX Quotation for New Director Incentive Shares

Argent Biopharma ( ($AU:RGT) ) just unveiled an update. Argent Biopharma has applied to the ASX for quotation...

2M ago

RGTLF FAQ

What was Argent Biopharma’s price range in the past 12 months?

Argent Biopharma lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.

What is Argent Biopharma’s market cap?

Argent Biopharma’s market cap is $3.04M.

When is Argent Biopharma’s upcoming earnings report date?

Argent Biopharma’s upcoming earnings report date is Aug 28, 2026 which is in 90 days.

How were Argent Biopharma’s earnings last quarter?

Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.027.

Is Argent Biopharma overvalued?

According to Wall Street analysts Argent Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Argent Biopharma pay dividends?

Argent Biopharma does not currently pay dividends.

What is Argent Biopharma’s EPS estimate?

Argent Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Argent Biopharma have?

Argent Biopharma has 111,109,580 shares outstanding.

What happened to Argent Biopharma’s price movement after its last earnings report?

Argent Biopharma reported an EPS of -$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Argent Biopharma?

Currently, no hedge funds are holding shares in RGTLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Argent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

258.94%

Trailing 12-Months

Asset Growth

-29.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Argent Biopharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.